Given the excitement and anticipation of increasingly more promising prophylactic treatments and gene therapies, the 2^nd Annual Hemophilia Drug Development Summit, once again unites leading pharma, biotech and academic KOLs working to translate and clinically develop longer acting and more efficacious therapies to overcome significant unmet medical need and hemophilia and other bleeding disorders.

Fuelled by current investment in the space and novel therapeutic strategies to improve current standard of care, the development of hemophilia therapeutics has been reinvigorated. Touted as an area of large unmet medical need but a well understood and defined disease profile, investment in this space is set to grow.

Attend the 2^nd Hemophilia Drug Development Summit to identify novel drug development strategies and overcome the shared translational, clinical development and delivery challenges to dramatically improve patient outcomes.

Join speakers from key companies such as Spark Therapeutics, uniQure, Bayer, Sanofi, Novo Nordisk, Sangamo to meet the demand and treatment goals of patients, in a changing treatment paradigm.